Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C
| Autor: | Epameinondas V. Tsianos, Haralampos J. Milionis, Gerasimos Baltayiannis, Spyridon Filis, Michael Economou, Leonidas Christou, Moses Elisaf |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Apolipoprotein B Blood lipids Gastroenterology Antiviral Agents Cholesterol LDL/*blood chemistry.chemical_compound Pegylated interferon Predictive Value of Tests Internal medicine medicine Humans Apolipoproteins B Retrospective Studies Cholesterol/*blood Hepatology biology Cholesterol business.industry Hepatitis C Odds ratio Cholesterol LDL Hepatitis C Chronic Middle Aged medicine.disease Antiviral Agents/*therapeutic use Apolipoproteins B/*blood chemistry Immunology biology.protein lipids (amino acids peptides and proteins) Female Hepatitis C Chronic/*blood/*drug therapy business Viral load medicine.drug Lipoprotein |
| Zdroj: | Journal of gastroenterology and hepatology. 23(4) |
| ISSN: | 1440-1746 |
| Popis: | Background: Hepatitis C virus (HCV) partially interacts with low-density lipoprotein (LDL) receptors, suggesting a role for lipids in regulating HCV clearance. Our aim was to study if baseline lipids can discriminate responders from non-responders among patients with HCV infection. Methods: A total of 109 HCV patients were studied. Laboratory measurements included serum lipids, aminotransferases and viral load, as well as HCV genotype determinations. Results: Responders (n = 53) had significantly higher serum baseline levels of total cholesterol, LDL cholesterol and apolipoprotein B compared to non-responders (n = 56). Multivariate logistic regression analysis showed that a 10 mg/dL increase in total cholesterol was associated with 3.02 higher odds of responding to treatment (95% CI 1.74–5.32, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text